Section Arrow
Quote
NRSN.NASDAQ
- NeuroSense Therapeutics Ltd
Quotes are at least 15-min delayed:2025/05/15 12:24 EDT
Last
 1.2
-0.0179 (-1.47%)
Day High 
1.28 
Prev. Close
1.2179 
1-M High
1.39 
Volume 
99.52K 
Bid
1.18
Ask
1.2
Day Low
1.19 
Open
1.28 
1-M Low
0.93 
Market Cap 
29.22M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.09 
20-SMA 1.04 
50-SMA 1.05 
52-W High 1.5 
52-W Low 0.512 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.54/-0.35
Enterprise Value
29.22M
Balance Sheet
Book Value Per Share
0.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0503+0.0157+45.38%-- 
PLRZPolyrizon Ltd0.0089-0.0037-29.37%-- 
ABPAbpro Holdings Inc0.1949+0.0299+18.12%-- 
ONCOOnconetix Inc0.0768-0.016-17.24%-- 
LYRALyra Therapeutics0.118+0.0063+5.64%-- 
Quotes are at least 15-min delayed：2025/05/15 12:24 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.